Diekema DJ, Jones RN (2001) Oxazolidinone antibiotics. Lancet 358:1975–1982. https://doi.org/10.1016/S0140-6736(01)06964-1

Article  CAS  PubMed  Google Scholar 

Hashemian SMR, Farhadi T, Ganjparvar M (2018) Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther 12:1759–1767. https://doi.org/10.2147/DDDT.S164515

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vinh DC, Rubinstein E (2009) Linezolid: a review of safety and tolerability. J Infect 59(Suppl 1):S59-74. https://doi.org/10.1016/S0163-4453(09)60009-8

Article  PubMed  Google Scholar 

ZYVOX®Highlights (Linezolid) | Pfizer Medical Information - US. Available online: https://www.pfizermedicalinformation.com/en-us/zyvox/highlights. Retrieved 1 September 2022

Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, Hafkin B, Le V, Remington J (2003) Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 47:1824–1831. https://doi.org/10.1128/aac.47.6.1824-1831.2003

Article  CAS  PubMed  PubMed Central  Google Scholar 

Butterfield JM, Lawrence KR, Reisman A, Huang DB, Thompson CA, Lodise TP (2012) Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of phase III and IV randomized clinical trial data. J Antimicrob Chemother 67:494–502. https://doi.org/10.1093/jac/dkr467

Article  CAS  PubMed  Google Scholar 

Discotto LF, Pucci MJ, Lawrence LE, Barrett JF (1998) 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 24–27, 1998, San Diego, CA, USA. Expert Opin Investig Drugs 7:2061–2077.https://doi.org/10.1517/13543784.7.12.2061

Zhanel GG, Shroeder C, Vercaigne L, Gin AS, Embil J, Hoban DJ (2001) A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins? Can J Infect Dis 12:379–390. https://doi.org/10.1155/2001/260651

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fung HB, Kirschenbaum HL, Ojofeitimi BO (2001) Linezolid: an oxazolidinone antimicrobial agent. Clin Ther 23:356–391. https://doi.org/10.1016/s0149-2918(01)80043-6

Article  CAS  PubMed  Google Scholar 

Volpi-Abadie J, Kaye AM, Kaye AD (2013) Serotonin syndrome. Ochsner J 13:533–540

PubMed  PubMed Central  Google Scholar 

Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM (2003) The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 96:635–642. https://doi.org/10.1093/qjmed/hcg109

Article  CAS  PubMed  Google Scholar 

Research C (2019) for D.E. and FDA Drug Safety Communication: serious CNS reactions possible when linezolid (Zyvox) is given to patients taking certain psychiatric medications. FDA 

Woytowish MR, Maynor LM (2013) Clinical relevance of linezolid-associated serotonin toxicity. Ann Pharmacother 47:388–397. https://doi.org/10.1345/aph.1R386

Article  CAS  PubMed  Google Scholar 

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA (2015) PRISMA-P group preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1. https://doi.org/10.1186/2046-4053-4-1

Article  PubMed  PubMed Central  Google Scholar 

Tokuyama R, Takahashi Y, Tomita Y, Suzuki T, Yoshida T, Iwasaki N, Kado N, Okezaki E, Nagata O (2001) Structure-activity relationship (SAR) studies on oxazolidinone antibacterial agents. 1. Conversion of 5-Substituent on Oxazolidinone. Chem Pharm Bull 49:347–352. https://doi.org/10.1248/cpb.49.347

Shi L, Yang Y, Li Z-L, Zhu Z-W, Liu C-H, Zhu H-L (2010) Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem 18:1659–1664. https://doi.org/10.1016/j.bmc.2009.12.065

Article  CAS  PubMed  Google Scholar 

Kumar B, Sheetal S, Mantha AK, Kumar V (2016) Recent developments on the structure–activity relationship studies of MAO inhibitors and their role in different neurological disorders. RSC Adv 6:42660–42683. https://doi.org/10.1039/C6RA00302H

Article  CAS  Google Scholar 

Mai A, Artico M, Valente S, Sbardella G, Turini P, Befani O, Vedova L, Agostinelli E (2005) 3-(1H-pyrrol-2-Yl)-2-oxazolidinones as novel monoamine oxidase type A inhibitors. MC 1:117–124. https://doi.org/10.2174/1573406053175247

Sutton J, Stroup J, Som M (2016) Linezolid-induced serotonin toxicity in a patient not taking monoamine oxidase inhibitors or serotonin receptor antagonists. Bayl Univ Med Cent Proc 29:214–215. https://doi.org/10.1080/08998280.2016.11929423

Article  PubMed  PubMed Central  Google Scholar 

Lv X, Alder J, Li L, O’Riordan W, Rybak MJ, Ye H, Zhang R, Zhang Z, Zhu X, Wilcox MH (2019) Efficacy and safety of tedizolid phosphate versus linezolid in a randomized phase 3 trial in patients with acute bacterial skin and skin structure infection. Antimicrob Agents Chemother 63:e02252-e2318. https://doi.org/10.1128/AAC.02252-18

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, Garrity-Ryan L, Das AF, Tzanis E, Eckburg PB et al (2019) Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med 380:528–538. https://doi.org/10.1056/NEJMoa1800170

Article  PubMed  Google Scholar 

Harbarth S, von Dach E, Pagani L, Macedo-Vinas M, Huttner B, Olearo F, Emonet S, Uckay I (2015) Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection. J Antimicrob Chemother 70:264–272. https://doi.org/10.1093/jac/dku352

Article  CAS  PubMed  Google Scholar 

Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P (2014) Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 14:696–705. https://doi.org/10.1016/S1473-3099(14)70737-6

Article  CAS  PubMed  Google Scholar 

Prokocimer P, De Anda C, Fang E, Mehra P, Das A (2013) Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 309:559. https://doi.org/10.1001/jama.2013.241

Article  CAS  PubMed  Google Scholar 

O’Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, Eckburg PB, Manley A, Steenbergen JN, Tzanis E et al (2019) Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis 19:1080–1090. https://doi.org/10.1016/S1473-3099(19)30275-0

Article  PubMed  Google Scholar 

Lee J-K, Lee JY, Kim DK, Yoon HI, Jeong I, Heo EY, Park YS, Jo YS, Lee JH, Park SS et al (2019) Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. Lancet Infect Dis 19:46–55. https://doi.org/10.1016/S1473-3099(18)30480-8

Article  CAS  PubMed  Google Scholar 

Kingsley J, Mehra P, Lawrence LE, Henry E, Duffy E, Cammarata SK, Pullman J (2016) A Randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother 71:821–829. https://doi.org/10.1093/jac/dkv411

Article  CAS  PubMed  Google Scholar 

Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW (2014) Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370:2169–2179. https://doi.org/10.1056/NEJMoa1310480

Article  CAS  PubMed  Google Scholar 

Awad SS, Rodriguez AH, Chuang Y-C, Marjanek Z, Pareigis AJ, Reis G, Scheeren TWL, Sanchez AS, Zhou X, Saulay M et al (2014) A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 59:51–61. https://doi.org/10.1093/cid/ciu219

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noel GJ, Draper MP, Hait H, Tanaka SK, Arbeit RD (2012) A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 56:5650–5654. https://doi.org/10.1128/AAC.00948-12

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J (2012) Linezolid in methicillin-resistant staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54:621–629. https://doi.org/10.1093/cid/cir895

Article  CAS  PubMed  Google Scholar 

Covington P, Davenport JM, Andrae D, O’Riordan W, Liverman L, McIntyre G, Almenoff J (2011) Randomized, double-blind, phase ii, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrob Agents Chemother 55:5790–5797. https://doi.org/10.1128/AAC.05044-11

Article  CAS  PubMed  PubMed Central  Google Scholar 

Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG, Corey GR, Das A, Fernandes P (2011) A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis 52:S520–S526. https://doi.org/10.1093/cid/cir167

Article  CAS  PubMed  Google Scholar 

Karkow DC, Kauer JF, Ernst EJ (2017) Incidence of serotonin syndrome with combined use of linezolid and serotonin reuptake inhibitors compared with linezolid monotherapy. J Clin Psychopharmacol 37:518–523. https://doi.org/10.1097/JCP.0000000000000751

Article  CAS  PubMed  Google Scholar 

Lodise TP, Patel N, Rivera A, Tristani L, Lazariu V, Vandewall H, McNutt LA (2013) Comparative evaluation of serotonin toxicity among veterans affairs patients receiving linezolid and vancomycin. Antimicrob Agents Chemother 57:5901–5911. https://doi.org/10.1128/AAC.00921-13

Article  CAS  PubMed  PubMed Central  Google Scholar 

Traver EC, Heil EL, Schmalzle SA (2022) A cross-sectional analysis of linezolid in combination with methadone or buprenorphine as a cause of serotonin toxicity. Open Forum Infect Dis 9:ofac331. https://doi.org/10.1093/ofid/ofac331

Bernard L, Stern R, Lew D, Hoffmeyer P (2003) Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis 36:1197–1197. https://doi.org/10.1086/374558

Article  CAS